CDK
Les inhibiteurs des kinases dépendantes des cyclines (CDK) sont des composés qui bloquent l'activité des CDK, un groupe de kinases protéiques qui régulent le cycle cellulaire, la transcription et d'autres processus cellulaires. Les CDK sont activées par leur liaison aux cyclines, et leur activité est cruciale pour la progression des cellules à travers les différentes phases du cycle cellulaire. Inhiber les CDK peut arrêter la division cellulaire, entraînant un arrêt du cycle cellulaire et l'apoptose, en particulier dans les cellules cancéreuses où les CDK sont souvent dysrégulées. Les inhibiteurs de CDK sont largement utilisés dans la recherche sur le cancer et ont un potentiel thérapeutique dans le traitement de divers cancers. Chez CymitQuimica, nous offrons une sélection complète d'inhibiteurs de CDK de haute qualité pour soutenir vos recherches sur le contrôle du cycle cellulaire, le cancer et le développement thérapeutique.
548 produits trouvés pour "CDK"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
WAY-322243
CAS :WAY-322243 has antibacterial and anti-inflammatory activity and has an inhibitory effect on CLK-1, which can be used to study Alzheimer's disease.Formule :C18H18N2O2SDegré de pureté :99.88%Couleur et forme :SoildMasse moléculaire :326.41JH-XI-10-02
CAS :JH-XI-10-02 selectively degrades CDK8 (IC50: 159 nM) through proteasome, sparing CDK8 mRNA and CDK19.Formule :C53H69N5O9Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :920.161JWZ-5-13
JWZ-5-13 is an effective CDK7 PROTAC degrader that significantly degrades CDK7 via the ubiquitin-proteasome system. JWZ-5-13 also exhibits antitumor activity.Formule :C54H66N10O6SMasse moléculaire :982.48875Cimpuciclib
CAS :Cimpuciclib is a cyclin-dependent kinase(CDK) inhibitor and antineoplastic.Formule :C30H35FN8OCouleur et forme :SolidMasse moléculaire :542.663Cdk2/Cyclin Inhibitory Peptide II
CAS :Cdk2/Cyclin Inhibitory Peptide II (Tat-LDL), a CDK2 inhibitor, demonstrates dose-dependent cytotoxic effects on U2OS osteosarcoma cells [1].Formule :C110H200N48O25Couleur et forme :SolidMasse moléculaire :2595.07CPS2
CAS :CPS2: potent, selective PROTAC CDK2 degrader. IC50=24nM, targets acute myeloid leukemia research.Formule :C38H42N12O10S2Couleur et forme :SolidMasse moléculaire :890.943-Methylthienyl-carbonyl-JNJ-7706621
CAS :Potent CDK inhibitor 3-Methylthienyl-carbonyl-JNJ-7706621, IC50: CDK1=6.4nM, CDK2=2nM, GSK-3=0.041μM; moderate on CDK4/VEGF-R2/FGF-R2.Formule :C14H14N6O3S2Couleur et forme :SolidMasse moléculaire :378.43CDK7-IN-7
CAS :CDK7-IN-7: Selective CDK7 inhibitor, IC50 < 50 nM (Patent CN112661745A).Formule :C20H20BrF3N6O2Couleur et forme :SolidMasse moléculaire :513.319YKL-5-124 TFA
CAS :YKL-5-124 TFA is a potent CDK7 inhibitor (IC50: 53.5 nM), more than 100x selective over CDK9/2, not active on CDK12/13, and disrupts the cell cycle.Formule :C30H34F3N7O5Couleur et forme :SolidMasse moléculaire :629.63IV-361
CAS :IV-361, an orally active and selective CDK7 inhibitor with a Ki value of less than or equal to 50 nM, demonstrates potent anti-cancer activity (US20190256531A1Formule :C23H32FN5O2SiCouleur et forme :SolidMasse moléculaire :457.625EGFR/CDK2-IN-2
EGFR/CDK2-IN-2 (compound 6a) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 19.6 nM and 87.9 nM, respectively.Formule :C49H32N12O2S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :884.99Multi-target kinase inhibitor 2
Compound 5K (Multi-target kinase inhibitor 2) is a multi-targeted kinase inhibitor demonstrating activity against EGFR, Her2, VEGFR2, and CDK2 with IC50 valuesDegré de pureté :98%Couleur et forme :Odour SolidBSJ-03-204 triTFA
BSJ-03-204 triTFA is a potent and selective Cereblon- and CDK-targeted PROTAC (PROteolysis TArgeting Chimera) featuring Palbociclib-based ligands for theFormule :C49H51F9N10O14Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1174.97CDK2/PIM1-IN-1
CDK2/PIM1-IN-1 is an inhibitor of the kinases CDK2 (IC50: 0.27 μM) and PIM1 (IC50: 0.67 μM). It can induce apoptosis (cell death) and reduce the expression of TNF-α, which promotes tumors. CDK2/PIM1-IN-1 exhibits antitumor activity.Couleur et forme :Odour SolidLSN3106729 hydrochloride
CAS :LSN3106729 hydrochloride, an Abemaciclib metabolite, is a CDK-inhibiting antitumor PROTAC CDK4/6 degrader.Formule :C25H29ClF2N8OCouleur et forme :SoildMasse moléculaire :531.00Olomoucine
CAS :Olomoucine hinders Cdk2, Cdc2, CDK5, ERK1, regulates the cell cycle, and fights melanoma; IC50s: 3-25 µM.
Formule :C15H18N6ODegré de pureté :99.77%Couleur et forme :White Crystalline PowderMasse moléculaire :298.34CDK7-IN-1
CAS :CDK7-IN-1, analog of YKL-5-124, inhibits cdk7 with IC50 < 100 nM.Formule :C28H35N7O3Couleur et forme :SolidMasse moléculaire :517.634BSJ-04-132
Selective Cdk4 degrader. Degrades Cdk4 in Molt-4 cells, with no effect on Cdk6 levels. Displays cereblon-dependent degradation.Couleur et forme :LiquidPROTAC FLT3/CDKs degrader-1
PROTACFLT3/CDKs degrader-1 (Compound C3) is an agent that degrades cyclin-dependent kinase (CDK2 with a DC50 of 18.73 nM) and FMS-like tyrosine kinase 3 (FLT3). It induces differentiation in HL-60 cells, achieving a 72.77% differentiation rate at 6.25 nM, and inhibits proliferation of acute myeloid leukemia (AML) cells, with an IC50 ranging from 2.9 to 37 nM. PROTACFLT3/CDKs degrader-1 demonstrates potential for improving the treatment of AML.Formule :C40H42N12O5Masse moléculaire :770.34011CDK6/9-IN-1
CAS :CDK6/9-IN-1, an oral dual inhibitor of CDK6/9, has IC50s of 40.5nM (CDK6) and 39.5nM (CDK9).Formule :C22H25ClN8OCouleur et forme :SolidMasse moléculaire :452.95EGFR/CDK2-IN-3
EGFR/CDK2-IN-3 (compound 4b) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 71.7 nM and 113.7 nM, respectively.Formule :C30H20N6OSDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :512.58BLINK15
BLINK15 is a blood-brain barrier-permeable Cdk5 inhibitor. It reduces CDK5 activity in CDK5/p35 (IC50= 29.34 nM) and CDK5/p25 (IC50= 12.08 nM) complexes. Additionally, BLINK15 exhibits antidiabetic and neuroprotective effects. It lowers blood glucose levels in type 2 diabetes (T2D) mice, enhances cognitive abilities, and diminishes neurodegenerative lesions.Couleur et forme :Odour SolidCDK12/13-IN-2
CDK12/13-IN-2 (Compound 24) is a covalent inhibitor of CDK12 and CDK13, exhibiting IC50 values of 15.5 nM and 12.2 nM, respectively. It effectively inhibits the proliferation of breast cancer cells and can be utilized in the research of triple-negative breast cancer.Formule :C24H22FN7O2Couleur et forme :SolidMasse moléculaire :459.48Maleimide-PEG8-Val-Ala-PAB-SNS032
Maleimide-Val-Ala-PAB-SNS032 is a conjugated compound used as an ADC toxin and linker. SNS032 acts as a CDK inhibitor, reducing cancer cell viability and arresting the cell cycle at the G1/S phase. Maleimide-Val-Ala-PAB functions as a cleavable ADC linker. Maleimide-Val-Ala-PAB-SNS032 is utilized in the synthesis of ADC molecules.Formule :C59H87N9O18S2Masse moléculaire :1273.56105CDK2 degrader 3
CAS :CDK2 degrader3 selectively degrades CDK2 and exhibits antitumor activity.Formule :C44H53ClN10O6SCouleur et forme :SolidMasse moléculaire :885.47PP-C8
PP-C8: PROTAC CDK12-Cyclin K degrader with DC50s 416/412 nM; synergizes with PARP inhibitor against TNBC.Formule :C43H51FN12O7Couleur et forme :SolidMasse moléculaire :866.94CDK1-IN-2
CAS :CDK1-IN-2 (cdk1 inhibitor 2) is a CDK1 inhibitor with IC50 of 5.8 μM.Formule :C17H11ClN2ODegré de pureté :98.53%Couleur et forme :SoildMasse moléculaire :294.73Ref: TM-T64373
1mg50,00€1mL*10mM (DMSO)103,00€5mg107,00€10mg170,00€25mg354,00€50mg567,00€100mg810,00€500mg1.644,00€CDK4/6-IN-23
CDK4/6-IN-23 (Compound 42) is a potent and selective inhibitor of CDK4/6, displaying an IC50 of 11 nM for CDK6. This compound significantly activates immune cells and enhances IL-3 production. In mice undergoing 5-FU chemotherapy, CDK4/6-IN-23 demonstrates dual bone marrow protection and immunomodulatory effects.Formule :C32H34FN7O4Couleur et forme :SolidMasse moléculaire :599.655CDK12-IN-4
CAS :CDK12-IN-4 is a pyrazolotriazine that inhibits CDK12 (IC50: 0.641 μM) with high ATP (2 mM) and spares CDK2/Cyclin E and CDK9/Cyclin T1 (IC50: >20 μM).Formule :C20H20F2N8OCouleur et forme :SolidMasse moléculaire :426.432CDK4/6-IN-11
CAS :CDK4/6-IN-11 is a potent PROTAC CDK4/6 degrader.Formule :C43H49N11O7Couleur et forme :SolidMasse moléculaire :831.92CDK12-IN-6
CAS :CDK12-IN-6, a pyrazolotriazine, strongly inhibits CDK12 (IC50 1.19 μM at 2 mM ATP), but not CDK2/Cyclin E or CDK9/Cyclin T1 (both IC50 >20 μM).Formule :C20H21F2N9Couleur et forme :SolidMasse moléculaire :425.448NecroIr2
NecroIr2, an iridium(III) compound, induces necroptosis in Cisplatin-resistant A549R lung cancer cells and disrupts mitochondria.Formule :C46H30ClIrN6O2Couleur et forme :SolidMasse moléculaire :926.44Cell Cycle Compound Library
A unique collection of xnum cell cycle related compounds for high throughput screening (HTS) and high content screening (HCS);
Couleur et forme :Odour Solid[pSer2, pSer5, pSer7]-CTD TFA
Substrate '[pSer2, pSer5, pSer7]-CTD (TFA)' for CDK7 phosphorylates RNA Pol II CTD at ser2, 5, 7.Formule :C98H138F3N21O39Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :2291.25PROTAC CDK9 degrader 4
CAS :PROTAC CDK9 degrader 4 is a CDK9 degrader that targets transcriptional regulation and has potential anticancer activity.Formule :C43H56N10O5Couleur et forme :SolidMasse moléculaire :792.97Abemaciclib metabolite M18
CAS :Abemaciclib M18 (LSN3106729), a potent CDK inhibitor with antitumor action, used in a PROTAC to degrade CDK4/6.Formule :C25H28F2N8ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :494.54JH-XVI-178
CAS :JH-XVI-178: potent CDK8/19 inhibitor with good pharmacokinetics, low clearance, moderate oral bioavailability.Formule :C22H22ClN7OCouleur et forme :SolidMasse moléculaire :435.92BSJ-5-63
CAS :BSJ-5-63 is an effective degrader of CDK12, CDK7, and CDK9. It reduces the protein expression of CDK12, CDK7, CDK9, RNAPII, and Cyclin K, and also decreases the mRNA expression of BRCA1 and BRCA2. BSJ-5-63 exhibits anticancer activity and holds potential for prostate cancer research.Formule :C52H74ClN9O6S2Couleur et forme :SolidMasse moléculaire :1020.78PROTAC CDK9 degrader-8
PROTAC CDK9 Degrader-8 (Compound 21) is a potent degrader of CDK9 with an IC50 of 0.01 μM, utilized in cancer research [1].Formule :C44H52Cl2N10O7Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :903.85CDK9/EZH2-IN-1
CAS :CDK9/EZH2-IN-1 is a dual-target inhibitor of CDK9 and EZH2 with IC50 values of 83.9 nM and 108.6 nM, respectively. It induces apoptosis and causes DNA double-strand breaks (DSB). Additionally, CDK9/EZH2-IN-1 inhibits the proliferation of MKN45, MDA-MB-453, and SW620 cancer cells, with respective IC50 values of 136.3 nM, 171.3 nM, and 315.7 nM.Formule :C47H59N11O4S2Couleur et forme :SolidMasse moléculaire :906.17MeBIO
CAS :MeBIO is an agonist of aryl hydrocarbon receptor, with IC50 of 44 and 55 μM for GSK-3 and CDK1/CyclinB, respectively. MeBIO does not affect GSK-3β.Formule :C17H12BrN3O2Degré de pureté :99.64%Couleur et forme :SolidMasse moléculaire :370.2Ref: TM-T21966
1mg39,00€5mg74,00€1mL*10mM (DMSO)86,00€10mg117,00€25mg220,00€50mg354,00€100mg520,00€500mg1.130,00€CDK4/6-IN-5
CAS :CDK4/6-IN-5 inhibits CDK4/6; Ki: 0.2 nM (CDK4/D1) & 4.4 nM (CDK6/D3). (WO2019207463A1, A93)Formule :C22H28ClFN6O4SCouleur et forme :SolidMasse moléculaire :527.01bio-THZ1
CAS :bio-THZ1 is a biotinylated version of THZ1. THZ1 is a selective and irreversibly covalent CDK7 inhibitor (IC50: 3.2 nM).Formule :C52H65ClN12O8SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1053.67CDK7-IN-2 hydrochloride hydrate
CAS :CDK7-IN-2 HCl hydrate is a potent, specific CDK7 enzyme inhibitor with significant anti-cancer effects.Formule :C26H42ClN7O4Couleur et forme :SolidMasse moléculaire :552.12A-130A
CAS :A-130A is a polycyclic polyether compound belonging to the nigericin group of antibiotics generated by Streptomyces hygroscopicus strain.Formule :C47H78O13Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :851.11CDK5-IN-1
CAS :CDK5-IN-1: Potent CDK5 inhibitor (<10 nM) used in kidney disease research.Formule :C24H25FN6O3SCouleur et forme :SolidMasse moléculaire :496.56SHR5428
SHR5428 is an orally active, selective, noncovalent inhibitor of CDK7, displaying potent enzymatic inhibition (IC50 = 2.3 nM) and effectively suppressingDegré de pureté :98%Couleur et forme :Odour SolidCDK2/Bcl2-IN-1
CDK2/Bcl2-IN-1 (compound 1) is a saponin-based inhibitor of CDK-2 (IC50=117.6 nM) that exhibits potent cytotoxic effects on cancer cells.Formule :C35H56O10SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :668.88BSJ-03-204
CAS :BSJ-03-204 is a selective Cdk4/6 degrader.Formule :C43H48N10O8Couleur et forme :SolidMasse moléculaire :832.9ZNL-05-044
ZNL-05-044, a CDK11 inhibitor, exhibits IC50 values of 0.23 μM for CDK11A and 0.27 μM for CDK11B, as determined by NanoBRET assay.Formule :C21H22Cl2N6OSDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :477.41
